References
- NORDCAN, Cancer statistics for the Nordic countries. [Internet]. Available from: http://www-dep.iarc.fr/nordcan/English/frame.asp.
- Alfred Witjes J, Lebret T, Comperat EM. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462–475.
- Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164–174.
- Djaladat H, Katebian B, Bazargani ST, et al. 90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study. World J Urol. 2017;35:907–911.
- Elmussareh M, Simonsen PC, Young M, et al. Correlation between organ-specific co-morbidities and complications in bladder cancer patients undergoing radical cystectomy. Scand J Urol. 2019;52:1–6.
- Jerlstrom T, Gardmark T, Carringer M, et al. Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. Scand J Urol. 2014;48:334–340.
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.
- Mitropoulos D, Artibani W, Biyani CS, et al. Validation of the Clavien–Dindo grading system in urology by the European Association of Urology Guidelines Ad Hoc Panel. Eur Urol Focus. 2018;4:608–613.
- Mansson A, Henningsohn L, Steineck G, et al. Neutral third party versus treating institution for evaluating quality of life after radical cystectomy. Eur Urol. 2004;46:195–199.
- Liedberg F, Gudjonsson S, Xu A, et al. Long-term third-party assessment of results after continent cutaneous diversion with Lundiana pouch. BJU Int. 2017;120:530–536.
- Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014;24:487–491.
- Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27:295–300.
- Berrum-Svennung I, Hedelin H, Holmäng S. Costs of radical cystectomy. Scand J Urol Nephrol. 2005;39:36–41.
- Bagi P, Nordsten CB, Kehlet H. Cystectomy for bladder cancer in Denmark during the 2006–2013 period. Dan Med J. 2016;63:pii: A5217.
- The Swedish Cystectomy Registry. [Internet]. Available from: https://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase–och-urinrorscancer/dokument/manual-cystektomiuppfoljning-170101-3.pdf.
- Meakins JL. Innovation in surgery: the rules of evidence. Am J Surg. 2002;183:399–405.
- Barkun JS, Barkun AN, Sampalis JS. Randomised controlled trial of laparoscopic versus mini cholecystectomy. The McGill Gallstone Treatment Group. Lancet (London, England). 1992;340:1116–1119.
- Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364:2128–2137.
- Cancercentrum annual report. [Internet]. 2017. Available from: https://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase–ochurinrorscancer/rapporter/urinblasa_arsrapport_2017_final.pdf.
- Milenkovic U, Akand M, Moris L, et al. Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. World J Urol. 2018;
- Liedberg F. Early complications and morbidity of radical cystectomy. Eur Urol Supp. 2010;9:25–30.
- Haynes AB, Weiser TG, Berry WR, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med. 2009;360:491–499.